Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore Raises SEK 30M as it Looks Toward IPO

NEW YORK – Qlucore said Wednesday that it has closed a private placement worth SEK 30 million ($3.5 million). Eiffel Investment Group led the round, with participation from other, unspecified "long-term strategic institutional and private investors," according to the Swedish bioinformatics technology developer.

Investors purchased 71,400 shares in this unnamed round at a price of SEK 420 per share, Qlucore said. That brings the total number of shares to 263,271, valuing the company at nearly SEK 110.6 million.

The Lund, Sweden-based vendor said that it would use the proceeds to expand its sales and technical teams as it prepares for an initial public offering in the next 12 months. The firm said that its newest market of cancer diagnostics now represents its largest potential for growth.

"Eiffel Investment Group is pleased to help fund the further development of Qlucore, from a worldwide recognized bioinformatics data analysis software company for precision diagnostics and research to a platform for precision diagnostics for clinical use in cancer, as a first target area, and a true enabler of precision medicine," Jean-François Paumelle, partner of Paris-based Eiffel Investment Group, said in a statement. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.